Acrobiosystems Co

Acrobiosystems Co EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 31.16 %. In the previous year, Year-over-Year EBITDA Growth was -7.22 % — a change of -531.77% (higher).

EBITDA Growth YoY

31.16 %

YoY

-531.77%

Last updated:

Year-over-Year EBITDA Growth of Acrobiosystems Co is 2025 31.16 % . Year-over-Year EBITDA Growth of Acrobiosystems Co was 2024 -7.22 % . It decreases by -531.77% higher compared to the previous year.

The Acrobiosystems Co EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2019
45.76 CNY
Jan 1, 2020
678.80 CNY
Jan 1, 2021
43.32 CNY
Jan 1, 2022
-7.86 CNY
Jan 1, 2023
-14.71 CNY
Jan 1, 2024
-7.22 CNY
Jan 1, 2025
31.16 CNY
The Acrobiosystems Co EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
31.16 %-531.77%
-7.22 %-50.96%
-14.71 %+87.22%
-7.86 %-118.14%
43.32 %-93.62%
678.80 %+1,383.30%
45.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Year-over-Year EBITDA Growth of Acrobiosystems Co is 31.16 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co